source
- Moonwalk Biosciences raises $70M to move RNAi obesity drug MW101 toward first-in-human trials in 2027Moonwalk Biosciences, an obesity drug developer backed by Eli Lilly, announced a $70 million Series B financing. The funding will support its lead RNAi candidate, MW101, which in mouse studies pro…
- Moonwalk Biosciences raises $70M to advance siRNA obesity therapyMoonwalk Biosciences announced it has secured $70 million in financing to move its obesity program into clinical testing. The funding will support development of a small interfering RNA (siRNA) th…